Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Shares Outstanding (2016 - 2025)

Regenxbio (RGNX) has 12 years of Shares Outstanding data on record, last reported at $50.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.71% year-over-year to $50.9 million; the TTM value through Dec 2025 reached $50.9 million, up 2.71%, while the annual FY2025 figure was $50.9 million, 2.71% up from the prior year.
  • Shares Outstanding reached $50.9 million in Q4 2025 per RGNX's latest filing, up from $50.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $50.9 million in Q4 2025 and bottomed at $42.5 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $45.9 million, with a median of $43.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: rose 14.3% in 2021, then rose 1.04% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $42.8 million in 2021, then rose by 1.09% to $43.3 million in 2022, then grew by 1.73% to $44.0 million in 2023, then grew by 12.49% to $49.5 million in 2024, then increased by 2.71% to $50.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $50.9 million in Q4 2025, $50.6 million in Q3 2025, and $50.4 million in Q2 2025.